The diabetes medication Canagliflozin attenuates alcoholic liver disease by reducing hepatic lipid accumulation via SIRT1-AMPK-mTORC1 signaling pathway

Update your browser to view ScienceDirect correctly.

Your technical details and browser version:

Request ID: 914fb6047f2df947-LAX IP: 47.97.18.252 UTC time: 2025-02-20T16:00:41+00:00 Browser: Mozilla/5.0 (X11; U; Linux x86_64; en-US; rv:1.9.1.4) Gecko/20091030 Gentoo Firefox/3.5.4